Live Breaking News & Updates on Specialty Medicines

Stay updated with breaking news from Specialty medicines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

20 Biggest Publicly Traded Biotech Companies

The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, reaching a staggering. ....

Democratic Republic Of The Congo , United States , United Kingdom , Ascendis Pharma , Bristol Myers Squibb , Amolyt Pharma , Myers Squibb , Fisher Scientific , Silicon Valley Bank , Alexion Pharmaceuticals , Africa Pathogen Genomics Initiative , Pharma Plc , Leukemia Lymphoma Society , Regeneron Pharmaceuticals , Generation Bio Co , Biggest Publicly Traded Biotech Companies , Biotech Companies , Vertex Pharmaceuticals , Gilead Sciences , Growing Biotech Companies , Market Growth , Technological Milestones , Biotechnology Sector , Horizon Therapeutics , Publicly Traded Biotech Companies , Growth Hormone ,

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk

NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments ....

United Kingdom , Daiichi Sankyo Europe Gmb , Sheldon Koenig , Alberico Catapano , Gillian Dsouza , Daiichi Sankyo , Oliver Appelhans , Daiichi Sankyo Europe , University Of Milan , European Atherosclerosis Society , European Society Of Cardiology , European Medicines Agency , European Commission , Head Of Europe Specialty Division , Esperion Therapeutics Inc , European Commissionas , Sankyo Europe Gmbh , Daiichi Sankyo , Esperion Therapeutics , Europe Specialty Division , Professor Alberico Catapano , Cholesterol Lowering , Bempedoic Acid , Inhibiting Regimen , Sankyo Europe , European Economic Area ,

GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook - GSK (NYSE:GSK)

Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix. Expectations soar with raised 2024 EPS and sales forecasts. ....

United States , Emma Walmsley , Pfizer Inc , Sterling Pounds , General Medicines , Specialty Medicines , Financial Times ,

GSK PLC reports Strong 1st quarter results with Sales and Earnings Growth

GSK PLC's Q1 2024 results show impressive growth in sales, profits, and earnings. CEO Emma Walmsley highlights strong performance and future growth prospects. ....

Emma Walmsley , Organisation For Economic Co , Development Pillar , Chief Executive Officer , Specialty Medicines , Operating Profit , Economic Co Operation , Core Operating Profit ,

COVID aside, vaccines and asthma drugs deliver strong quarter for GSK

According to GSK, the company has started 2024 strongly, with business momentum across all product areas. ....

City Of , United Kingdom , Emma Walmsley , Aiolos Bio , Smithkline Beecham , Constant Exchange , Rd Research Development , Valley Forge , Specialty Medicines , General Medicines , Constant Exchange Rates , Chief Executive Officer , Quarter Results , Average Manufacturer Price , Thymic Stromal Lymphopoietin , Glaxo Wellcome , Southeastern Pa , Omepage Top Stories ,